CWIAX
Price
$82.59
Change
+$0.54 (+0.66%)
Updated
Jun 2 closing price
Net Assets
151.89B
HEORX
Price
$21.43
Change
+$0.25 (+1.18%)
Updated
Jun 2 closing price
Net Assets
132.25M
Interact to see
Advertisement

CWIAX vs HEORX

Header iconCWIAX vs HEORX Comparison
Open Charts CWIAX vs HEORXBanner chart's image
CWIAX vs HEORX Comparison Chart in %
View a ticker or compare two or three
VS
CWIAX vs. HEORX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CWIAX is a Buy and HEORX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
CWIAX has more cash in the bank: 152B vs. HEORX (132M). CWIAX pays higher dividends than HEORX: CWIAX (1.33) vs HEORX (0.00). CWIAX was incepted earlier than HEORX: CWIAX (24 years) vs HEORX (10 years). HEORX (1.53) is less costly to investors than CWIAX (0.75). HEORX is a more actively managed with annual turnover of: 61.00 vs. CWIAX (44.00). HEORX has a lower initial minimum investment than CWIAX: HEORX (0) vs CWIAX (250). HEORX annual gain was more profitable for investors over the last year : 25.70 vs. CWIAX (22.44). CWIAX return over 5 years is better than : 38.19 vs. HEORX (26.72).
CWIAXHEORXCWIAX / HEORX
Total Expense Ratio0.751.4153%
Annual Report Gross Expense Ratio0.751.5349%
Fund Existence24 years10 years-
Gain YTD15.65219.32481%
Front Load4%N/A-
Min. Initial Investment2500-
Min. Initial Investment IRAN/AN/A-
Net Assets152B132M115,152%
Annual Yield % from dividends1.330.00-
Returns for 1 year22.4425.7087%
Returns for 3 years54.6543.05127%
Returns for 5 years38.1926.72143%
Returns for 10 years122.6398.80124%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CSHAX12.600.20
+1.61%
NYLI Cushing® MLP Premier Class A
JCPRX25.76N/A
N/A
JPMorgan US Large Cap Core Plus R5
OIEIX26.19N/A
N/A
JPMorgan Equity Income A
RYBOX65.18N/A
N/A
Rydex Biotechnology A
PSKCX23.33N/A
N/A
Virtus KAR Mid-Cap Growth C